Case report: progressive familial intrahepatic cholestasis type 3 with compound heterozygous ABCB4 variants diagnosed 15 years after liver transplantation.

Published on Nov 30, 2020in BMC Medical Genetics1.585
· DOI :10.1186/S12881-020-01173-0
Mariam Goubran1
Estimated H-index: 1
(University of Alberta Hospital),
Ayodeji Aderibigbe1
Estimated H-index: 1
(University of Alberta Hospital)
+ 4 AuthorsAndrew L. Mason54
Estimated H-index: 54
(U of A: University of Alberta)
Sources
Abstract
Progressive familial intrahepatic cholestasis (PFIC) type 3 is an autosomal recessive disorder arising from mutations in the ATP-binding cassette subfamily B member 4 (ABCB4) gene. This gene encodes multidrug resistance protein-3 (MDR3) that acts as a hepatocanalicular floppase that transports phosphatidylcholine from the inner to the outer canalicular membrane. In the absence of phosphatidylcholine, the detergent activity of bile salts is amplified and this leads to cholangiopathy, bile duct loss and biliary cirrhosis. Patients usually present in infancy or childhood and often progress to end-stage liver disease before adulthood. We report a 32-year-old female who required cadaveric liver transplantation at the age of 17 for cryptogenic cirrhosis. When the patient developed chronic ductopenia in the allograft 15 years later, we hypothesized that the patient’s original disease was due to a deficiency of a biliary transport protein and the ductopenia could be explained by an autoimmune response to neoantigen that was not previously encountered by the immune system. We therefore performed genetic analyses and immunohistochemistry of the native liver, which led to a diagnosis of PFIC3. However, there was no evidence of humoral immune response to the MDR3 and therefore, we assumed that the ductopenia observed in the allograft was likely due to chronic rejection rather than autoimmune disease in the allograft. Teenage patients referred for liver transplantation with cryptogenic liver disease should undergo work up for PFIC3. An accurate diagnosis of PFIC 3 is key for optimal management, therapeutic intervention, and avoidance of complications before the onset of end-stage liver disease.
References27
Newest
#1Elodie Mareux (Université Paris-Saclay)H-Index: 2
#2Martine Lapalus (Université Paris-Saclay)H-Index: 2
Last. Emmanuel Jacquemin (Université Paris-Saclay)H-Index: 23
view all 13 authors...
BACKGROUND & AIM: The canalicular bile salt export pump (BSEP/ABCB11) of hepatocytes is the main adenosine triphosphate (ATP)-binding cassette (ABC) transporter responsible for bile acid secretion. Mutations in ABCB11 cause several cholestatic diseases, including progressive familial intrahepatic cholestasis type 2 (PFIC2) often lethal in absence of liver transplantation. We investigated in vitro the effect and potential rescue of a BSEP mutation by ivacaftor, a clinically approved cystic fibros...
8 CitationsSource
#1Nicholas D. WeberH-Index: 1
#1Nicholas D. WeberH-Index: 10
Last. Cristian Smerdou (University of Navarra)H-Index: 24
view all 8 authors...
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease caused by mutations in the ABCB4 gene, resulting in a reduction in biliary phosphatidylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we report results from treating two- or five-week-old Abcb4−/− mice with an AAV vector expressing human ABCB4, resulting in significant decre...
7 CitationsSource
#1Sem J. Aronson (UvA: University of Amsterdam)H-Index: 6
#2Robert S. Bakker (UvA: University of Amsterdam)H-Index: 1
Last. Piter J. Bosma (UvA: University of Amsterdam)H-Index: 36
view all 12 authors...
Background & Aims Progressive familial intrahepatic cholestasis type 3 (PFIC3), for which there are limited therapeutic options, often leads to end-stage liver disease before adulthood due to impaired ABCB4-dependent phospholipid transport to bile. Using adeno-associated virus serotype 8 (AAV8)-mediated gene therapy, we aimed to restore the phospholipid content in bile to levels that prevent liver damage, thereby enabling stable hepatic ABCB4 expression and long-term correction of the phenotype ...
15 CitationsSource
#1Laura N. Bull (UCSF: University of California, San Francisco)H-Index: 31
#2Richard J. Thompson ('KCL': King's College London)H-Index: 30
Author(s): Bull, LN; Thompson, RJ | Abstract: Genetic cholestasis has been dissected through genetic investigation. The major PFIC genes are now described. ATP8B1 encodes FIC1, ABCB11 encodes BSEP, ABCB4 encodes MDR3, TJP2 encodes TJP2, NR1H4 encodes FXR, and MYO5B encodes MYO5B. The full spectra of phenotypes associated with mutations in each gene are discussed, along with our understanding of the disease mechanisms. Differences in treatment response and targets for future treatment are emergin...
49 CitationsSource
#1Jean-Louis Delaunay (University of Paris)H-Index: 6
#2Alix Bruneau (University of Paris)H-Index: 2
Last. Tounsia Aït-Slimane (University of Paris)H-Index: 7
view all 10 authors...
ABCB4 (MDR3) is an ATP-binding cassette (ABC) transporter expressed at the canalicular membrane of hepatocytes where it mediates phosphatidylcholine (PC) secretion. Variations in the ABCB4 gene are responsible for several biliary diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease that can be lethal in the absence of liver transplantation. In this study, we investigated the effect and potential rescue of ABCB4 missense variations that reside in the hi...
27 CitationsSource
#1Henkjan J. Verkade (UMCG: University Medical Center Groningen)H-Index: 57
#2Jorge A. Bezerra (Cincinnati Children's Hospital Medical Center)H-Index: 30
Last. Claus Petersen (MHH: Hannover Medical School)H-Index: 28
view all 12 authors...
Summary Biliary Atresia and other cholestatic childhood diseases are rare conditions affecting the function and/or anatomy along the canalicular-bile duct continuum, characterised by onset of persistent cholestatic jaundice during the neonatal period. Biliary atresia (BA) is the most common among these, but still has an incidence of only 1 in 10–19,000 in Europe and North America. Other diseases such as the genetic conditions, Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Choles...
86 CitationsSource
#1Hyojin Park (Ewha Womans University)H-Index: 37
#2Tae Hee Kim (Ewha Womans University)H-Index: 9
Last. Ji Ha Choi (Ewha Womans University)H-Index: 16
view all 10 authors...
Multidrug resistance 3 (MDR3), encoded by the ATP-binding cassette, subfamily B, member 4 gene (ABCB4), localizes to the canalicular membrane of hepatocytes and translocates phosphatidylcholine from the inner leaflet to the outer leaflet of the canalicular membrane. Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare hepatic disease caused by genetic mutations of ABCB4. In this study, we characterized 8 ABCB4 mutations found in PFIC3 patients, using in vitro molecular assays. ...
14 CitationsSource
#2Sara AnduezaH-Index: 3
Last. Luis Fernando Carballo Álvarez (Hospital Universitario La Paz)H-Index: 12
view all 5 authors...
Multidrug resistance protein 3 (MDR3, ABCB4) is a hepatocellular membrane protein that mediates biliary secretion of phosphatidylcholine. Null mutations in ABCB4 gene give rise to severe early-onset cholestatic liver disease. We have previously shown that the disease-associated mutations p.G68R, p.G228R, p.D459H, and p.A934T resulted in retention of ABCB4 in the endoplasmic reticulum, thus failing to target the plasma membrane. In the present study, we tested the ability of two compounds with ch...
27 CitationsSource
#1Salih Boga (Yale University)H-Index: 3
#2Dhanpat Jain (Yale University)H-Index: 47
Last. Michael L. Schilsky (Yale University)H-Index: 46
view all 3 authors...
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7. Here we report on an older patient, aged 15, who presented with biochemical testing that led to an initial consideration of a diagnosis of Wilson disease (WD) resulting in a delayed diagnosis of PFIC3. Diagnosis of PFIC3 was later confirmed by molecular studies that ...
10 CitationsSource
#1Emmanuel Gonzales (University of Paris-Sud)H-Index: 23
#2Brigitte Grosse (University of Paris-Sud)H-Index: 11
Last. Emmanuel Jacquemin (University of Paris-Sud)H-Index: 23
view all 8 authors...
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4-phenylbutyrate (4-PB), have been shown to partially correct mistrafficking. Four PFIC2 patients harboring at least one missense mutation (p.G982R,...
66 CitationsSource
Cited By1
Newest
Abstract Prune belly syndrome (PBS) results in a total lack of abdominal musculature. Abdominal muscles have an important function during inspiration and expiration. This puts the patient at risk for respiratory complications since they have a very limited ability to cough up secretions. Patients in an intensive care unit (ICU) with PBS who receive mechanical ventilation are at even greater risk for respiratory complications. We review the function of the abdominal muscles in breathing and delin...
Source